Welcome to our dedicated page for Eli Lilly & Co. news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly & Co. stock.
Eli Lilly and Company (NYSE: LLY), founded in 1876 by Colonel Eli Lilly, is a global leader in the pharmaceutical industry, headquartered in Indianapolis, Indiana. With operations in 18 countries and products sold in approximately 125 countries, Eli Lilly is dedicated to pioneering life-changing discoveries through innovative drug development. The company focuses on several therapeutic areas including neuroscience, cardiometabolic, cancer, and immunology.
Key products in Eli Lilly’s portfolio include Verzenio for cancer treatment; Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes management; and Taltz and Olumiant for immunology. The company's recent financial performance has been robust, with Q1 2024 revenues increasing by 26% year-over-year to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.
Eli Lilly continues to expand its manufacturing capabilities to meet growing demand, recently investing $5.3 billion in its Lebanon, Indiana site. This commitment supports the production of key therapies, particularly for chronic diseases like obesity and type 2 diabetes. The company’s innovative endeavors include the development of new treatments such as the once-weekly insulin efsitora alfa, which showed promising results in phase 3 trials for type 2 diabetes.
The company is also advancing its pipeline of oncology treatments with presentations of data on products like Verzenio, Retevmo, olomorasib, and imlunestrant at major medical conferences. Furthermore, Eli Lilly announced a major leadership change with Melissa Seymour joining as Executive Vice President of Global Quality, ensuring the sustained excellence of their product offerings.
Eli Lilly’s commitment to addressing significant health challenges is evident in its diverse product pipeline and ongoing clinical trials. The company remains focused on improving patient outcomes globally by harnessing advancements in biotechnology, chemistry, and genetic medicine.
Eli Lilly and Company (NYSE: LLY) declared a dividend of $1.30 per share for the second quarter of 2024. The dividend will be paid on June 10, 2024, to shareholders of record as of May 16, 2024. Lilly is a leading medicine company with a history of life-changing discoveries, helping over 51 million people worldwide. The company focuses on developing innovative solutions for diabetes, obesity, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers.
Lilly reported a 26% increase in revenue in Q1 2024, driven by strong sales of Mounjaro, Zepbound, Verzenio, and Jardiance. The company saw positive pipeline progress with significant results from Phase 3 trials and various submissions. Q1 2024 EPS increased by 66%, and the full-year revenue guidance was raised by $2 billion. Key financials and product revenue highlights were discussed in the press release.
FAQ
What is the current stock price of Eli Lilly & Co. (LLY)?
What is the market cap of Eli Lilly & Co. (LLY)?
What are Eli Lilly's core business areas?
What are some of Eli Lilly's key products?
How did Eli Lilly perform financially in Q1 2024?
What recent investments has Eli Lilly made?
Who is the new Executive Vice President of Global Quality at Eli Lilly?
What are some recent clinical trial results shared by Eli Lilly?
In how many countries does Eli Lilly operate?
What is the significance of Eli Lilly's recent investment in Lebanon, Indiana?
What is the focus of Eli Lilly's ongoing research and development?
What are some common side effects of Eli Lilly's product Mounjaro?
